Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin/molgramostim- Reponex Pharmaceuticals

Drug Profile

Fosfomycin/molgramostim- Reponex Pharmaceuticals

Alternative Names: RNX-023

Latest Information Update: 26 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reponex Pharmaceuticals
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antibronchitics; Antifibrotics; Antiulcers; Chemoprotectants; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Recombinant proteins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Granulocyte-macrophage colony stimulating factor replacements; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • Preclinical Varicose ulcer; Wounds

Most Recent Events

  • 26 Dec 2022 No recent reports on development identified – phase II for Crohn's disease in Denmark (Intraluminal) (Reponex Pharmaceuticals pipeline, December 2022)
  • 07 Oct 2020 Preclinical trials in Varicose ulcer in Denmark (unspecified route) (Reponex Pharmaceuticals pipeline, October 2020)
  • 07 Oct 2020 Preclinical trials in Wounds in Denmark (unspecified route) (Reponex Pharmaceuticals pipeline, October 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top